Journal of Interdisciplinary Genomics

Interdisciplinary Society of Genetic & Genomic Medicine (유전의학융합회)
권호 표지
DOI QR코드

DOI QR Code

Clinical Application of Chromosomal Microarray for Germline Disorders

  • Received : 2023.08.25
  • Accepted : 2023.10.13
  • Published : 2023.10.31
Download PDF
⟨ Previous Next ⟩

Abstract

Chromosomal microarray (CMA) is primarily recommended for detecting clinically significant copy number variants (CNVs) in the genetic diagnosis of developmental delay, intellectual disability, autism, and congenital malformations. Prenatal CMA is recommended when a fetus has major congenital malformations. The main principles of CMA can be divided into array comparative genomic hybridization and single-nucleotide polymorphism arrays. In the current CMA platforms, these two principles are combined, and detection of genetic abnormalities including CNVs and absence of heterozygosity is facilitated. In this review, I described practical assessment of CMA testing regarding to laboratory management of CMA, interpretation of CNVs, and special considerations for comprehensive genetic counseling.

Keywords

References

  1. Zneimer SM. Cytogenetic abnormalities: Chromosomal, FISH and Microarray-Based Clinical Reporting. 1st ed. ChiChester, UK: Wiley-Blackwell, 2014:3.
  2. Szuhai K. Array-CGH and SNP-Arrays, the New Karyotype. In: Jordan B, ed. Microarrays in Diagnostics and Biomarker Development: Current and Future Applications. Berlin, Heidelberg: Springer, 2012:39-52.
  3. Gonzales PR, Andersen EF, Brown TR, Horner VL, Horwitz J, Rehder CW, et al. Interpretation and reporting of large regions of homozygosity and suspected consanguinity/uniparental disomy, 2021 revision: a technical standard of the American College of Medical Genetics and Genomics (ACMG). Genet Med 2022;24: 255-61. doi: 10.1016/j.gim.2021.10.004.
  4. Uddin M, Thiruvahindrapuram B, Walker S, Wang Z, Hu P, Lamoureux S, et al. A high-resolution copy-number variation resource for clinical and population genetics. Genet Med 2015;17:747-52. doi: 10.1038/gim.2014.178.
  5. Zahir FR, Marra MA. Use of Affymetrix Arrays in the Diagnosis of Gene Copy-Number Variation. Curr Protoc Hum Genet 2015; 85:8.13.1-8.13.13. doi: 10.1002/0471142905.hg0813s85.
  6. Miller DT, Adam MP, Aradhya S, Biesecker LG, Brothman AR, Carter NP, et al. Consensus statement: chromosomal microarray is a first-tier clinical diagnostic test for individuals with developmental disabilities or congenital anomalies. Am J Hum Genet 2010;86:749-64. doi: 10.1016/j.ajhg.2010.04.006.
  7. Committee on Genetics and the Society for Maternal-Fetal Medicine. Committee Opinion No.682: microarrays and next-generation sequencing technology: the use of advanced genetic diagnostic tools in obstetrics and gynecology. Obstet Gynecol 2016; 128:e262-8. doi: 10.1097/AOG.0000000000001817.
  8. Wapner RJ, Martin CL, Levy B, Ballif BC, Eng CM, Zachary JM, et al. Chromosomal microarray versus karyotyping for prenatal diagnosis. N Engl J Med 2012;367:2175-84. doi: 10.1056/NEJMoa1203382.
  9. Shao L, Akkari Y, Cooley LD, Miller DT, Seifert BA, Wolff DJ, et al. ACMG Laboratory Quality Assurance Committee. Chromosomal microarray analysis, including constitutional and neoplastic disease applications, 2021 revision: a technical standard of the American College of Medical Genetics and Genomics (ACMG). Genet Med 2021;23:1818-29. doi: 10.1038/s41436-021-01214-w.
  10. Seol CA, Ha JS, Won D, Kim IS. Practical guidelines for chromosomal microarray analysis for constitutional abnormalities: part I, general and prenatal. Lab Med Online 2023;13:141-53. doi. org/10.47429/lmo.2023.13.3.141.
  11. Won D, Seol CA, Ha JS, Kim IS. Practical guidelines for chromosomal microarray analysis for constitutional abnormalities: part II, reporting and interpretation. Lab Med Online 2023;13:154-64. doi.org/10.47429/lmo.2023.13.3.154.
  12. Riggs ER, Andersen EF, Cherry AM, Kantarci S, Kearney H, Patel A, et al. Technical standards for the interpretation and reporting of constitutional copy-number variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics (ACMG) and the Clinical Genome Resource (ClinGen). Genet Med 2020;22:245-57. doi: 10.1038/s41436-019-0686-8.
  13. Thaxton C, Good ME, DiStefano MT, Luo X, Andersen EF, Thorland E, et al.; ClinGen Gene Curation Working Group; ClinGen Dosage Sensitivity Working Group. Utilizing ClinGen gene-disease validity and dosage sensitivity curations to inform variant classification. Hum Mutat 2022;43:1031-40. doi: 10.1002/humu.24291.
  14. Mikhail FM, Biegel JA, Cooley LD, Dubuc AM, Hirsch B, Horner VL, et al. Technical laboratory standards for interpretation and reporting of acquired copy-number abnormalities and copy-neutral loss of heterozygosity in neoplastic disorders: a joint consensus recommendation from the American College of Medical Genetics and Genomics (ACMG) and the Cancer Genomics Consortium (CGC). Genet Med 2019;21:1903-16. doi: 10.1038/s41436-019-0545-7.
  15. Miller DT, Lee K, Abul-Husn NS, Amendola LM, Brothers K, Chung WK, et al.; ACMG Secondary Findings Working Group. ACMG SF v3.2 list for reporting of secondary findings in clinical exome and genome sequencing: a policy statement of the American College of Medical Genetics and Genomics (ACMG). Genet Med 2023;25:100866. doi: 10.1016/j.gim.2023.100866.
  16. Newman S, Hermetz KE, Weckselblatt B, Rudd MK. Next-generation sequencing of duplication CNVs reveals that most are tandem and some create fusion genes at breakpoints. Am J Hum Genet 2015;96:208-20. doi: 10.1016/j.ajhg.2014.12.017.
  17. Smith A, Hung D. The dilemma of diagnostic testing for PraderWilli syndrome. Transl Pediatr 2017;6:46-56. doi: 10.21037/tp.2016.07.04.
  18. Maya I, Sharony R, Yacobson S, Kahana S, Yeshaya J, Tenne T, et al. When genotype is not predictive of phenotype: implications for genetic counseling based on 21,594 chromosomal microarray analysis examinations. Genet Med 2018;20:128-31. doi: 10.1038/gim.2017.89.
  19. Armour CM, Dougan SD, Brock JA, Chari R, Chodirker BN, DeBie I, et al.; On-Behalf-Of the Canadian College of Medical Geneticists. Practice guideline: joint CCMG-SOGC recommendations for the use of chromosomal microarray analysis for prenatal diagnosis and assessment of fetal loss in Canada. J Med Genet 2018;55:215-21. doi: 10.1136/jmedgenet-2017-105013.
  20. Seol CA. Clinical application of prenatal chromosomal microarray. J Genet Med 2022;19:43-8. doi.org/10.5734/JGM.2022.19.2.43.
  21. Yang X, Song Z, Wu C, Wang W, Li G, Zhang W, et al. Constructing a database for the relations between CNV and human genetic diseases via systematic text mining. BMC Bioinformatics 2018; 19(Suppl 19):528. doi: 10.1186/s12859-018-2526-2.